EGFR and neoplasm: For example, although promising preclinical results have been obtained with ErbB-targeting agents in suppressing cholangiocarcinoma cells both in vitro and in vivo, current clinical ErbB-directed therapies demonstrated only very limited anti-tumor activity [8].